Novo A/S leads $18 mln Series B funding in Nora Therapeutics

Novo A/S has led an $18 million Series B funding in Nora Therapeutics, a biotechnology company focused on developing therapeutics to address needs in reproductive medicine. Other participants in the funding round included all Series A investors -- Burrill & Company, Prospect Venture Partners, Rho Ventures and Vivo Capital. Heath Lukatch, partner at Novo Ventures, will join the company's board of directors.

North AmericaUSBriefs